TuHURA Biosciences (HURA) Q1 2026 earnings summary

Executive summary

• Clinical-stage immuno-oncology company advancing IFx-2.0, TBS-2025, and ADC programs, with key milestones expected in 2026 and 2027.

• Net loss of $7.5 million for Q1 2026, with no product revenue and an accumulated deficit of $148.7 million as of March 31, 2026.

• Secured a $50 million credit facility, extending cash runway into 2028 and providing operational flexibility.

• Strengthened leadership with strategic appointments to clinical and operational roles.

Financial highlights

• Cash and cash equivalents totaled $6.3 million at March 31, 2026.

• Q1 2026 net loss was $7.5 million, compared to $6.7 million in Q1 2025.

• Research and development expenses increased to $5.2 million from $4.6 million year-over-year.

• General and administrative expenses rose to $2.3 million from $2.1 million year-over-year.

• Net cash flows from financing activities were $7.2 million in Q1 2026.

Outlook and guidance

• Existing capital resources, including the $50 million credit facility, expected to fund operations into the end of 2028.

• Anticipates Orphan Drug Designation for IFx-2.0 in MCC in 1H 2026 and topline Phase 3 results in 2H 2027.

• Plans to initiate Phase 1b/2 trial for TBS-2025 in mutNPM1 r/r AML in 2H 2026.

• Expects to select lead ADC for proof-of-concept study in AML in 1H 2026.